THCP, HHCPO, H4-CBD: status, risks, and limits of screening
Partager
Why did the ANSM make this decision?
The National Agency for the Safety of Medicines and Health Products based this decision on reports of serious effects submitted by addiction monitoring centers, as well as on the risks of abuse and dependence.
These molecules can mimic the psychoactive effects of THC with a potency and composition often difficult to predict. Products sold as flowers, resins, liquids, sprays, or candies may not match the labeling provided.
Which families are concerned?
The decision notably targets two main categories.
Hemisynthetic or derivative cannabinoids
- H4-CBD and H2-CBD;
- certain derivatives built around a benzo[c]chromene core, including HHCPO and THCP;
- other molecules defined by the official decision.
Fully synthetic cannabinoids
The list also includes several purely chemical substances, such as 5F-Cumyl-Pegaclone, Cumyl-CH-Megaclone, 7APAICA, and various derivatives. The exact regulatory list should be consulted on the ANSM website or in the published decision.
What serious effects have been reported?
The ANSM cites vomiting, loss of consciousness, seizures, coma, severe anxiety, paranoia, tachycardia, hypertension, chest pain, and kidney damage. Severity depends on the molecule, concentration, mode of consumption, mixtures, and individual vulnerability.
Does a standard THC test detect THCP or HHCPO?
It should not be assumed. Rapid immunochemical tests look for specific molecules or metabolites. Cross-reactivity is sometimes possible but is neither systematic nor sufficient to precisely identify the consumed substance.
The ANSM indicates that the cannabinoids concerned are not properly detected by a standard urinary screening in the context of intoxication. Specific toxicological analysis by chromatography coupled with mass spectrometry may be necessary.
- a negative THC test does not exclude exposure to a synthetic cannabinoid;
- a positive result alone does not identify the exact product;
- a rapid test does not replace specialized toxicological analysis;
- the choice of the panel must correspond to the substance actually sought.
Can one test positive after using a product presented as CBD?
Yes. A product sold as CBD may contain THC, a psychoactive derivative, or a composition different from what is indicated. The legality of the label or point of sale does not guarantee the actual composition nor a negative screening result.
What prevention measures for companies and families?
- do not rely on commercial names like “legal CBD,” “new molecule,” or “THC-free” without reliable analysis;
- inform about the risks of highly concentrated or uncertain origin products;
- plan a course of action in case of malaise or intoxication;
- choose tests that truly cover the families sought;
- refer to a doctor, a CSAPA, or Drogues Info Service in case of usage difficulties.
View specialized urine testsRequest advice
